Newly Diagnosed Mantle Cell Lymphoma Treatment Practices
A hematologist-oncologist provides comprehensive insights on the treatment of newly diagnosed patients with mantle cell lymphoma.
Treating Relapsed/Refractory Follicular Lymphoma
The Oncology Brothers and Pallawi Torka, MD, review treatment options for patients with relapsed/refractory follicular lymphoma.
Navigating CML: Tools to Empower Patients and Caregivers
Joannie Clements, a patient advocate, provides insights on helping newly diagnosed patients with CML and their caregivers navigate the complexities of diagnosis, and Claire Saxton outlines resources available for them.
Understanding CML: Your Journey from Diagnosis to Treatment
A panel of experts on introduce a discussion on chronic myeloid leukemia (CML) with an overview of the disease, focusing on its subtypes and characteristics.
Treatment Algorithm for Follicular Lymphoma
Pallawi Torka, MD, joins the Oncology Brothers to discuss patient workup and treatment practices in follicular lymphoma, highlighting the PRIMA study and the role of maintenance therapy.
Selinexor, HER2-Targeting ADC May Provide Options for Endometrial Cancer
Ritu Salani, MD, discussed investigational endometrial cancer treatment options for patients with varying subtypes of endometrial cancer.
Comparable Safety Observed in Dostarlimab for Endometrial Cancer Subtypes
The second interim analysis of the phase 3 RUBY trial found the safety profile was consistent with the first interim analysis and no new deaths due to AEs were observed.
Dostarlimab Benefits Appear More Pronounced in dMMR Endometrial Cancer
The phase 3 RUBY trial evaluated dostarlimab in combination with carboplatin/paclitaxel in patients with primary advanced or recurrent endometrial cancer.
Afami-cel Approval in Sarcoma May Offer More Readily Accessible Therapy
Accelerated approval of afami-cel may expand access to therapy for patients who are unable to live near certain treatment centers.
Adverse Event Considerations in DLBCL
Medical oncologists conclude their discussion with a review of the toxicity profiles of treatments for diffuse large B-cell lymphoma.
Treatment Algorithm for Relapsed/Refractory DLBCL
Carla Casulo, MD, and the Oncology Brothers review the treatment algorithm for patients with relapsed/refractory DLBCL.
Treatment Practices for Stage III/IV DLBCL
The Oncology Brothers and Carla Casulo, MD, discuss treatment practices for patients with stage III or IV diffuse large B-cell lymphoma.
First-Line Treatment of Stage I/II DLBCL
A hematologist-oncologist joins the Oncology Brothers do discuss first-line treatment practices for patients with stage I or II diffuse large B-cell lymphoma.
Biopsy Practices in DLBCL
Carla Casulo, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to provide clinical insights on biopsy practices and discuss the importance of cell of origin in treating diffuse large B-cell lymphoma (DLBCL).
Exploring the Future of ctDNA and Novel Treatment Strategies
Panelists offer concluding perspectives on the future role of circulating tumor DNA in colorectal cancer management.
“Exciting” Response Durability Data Support Afami-cel Approval in Sarcoma
Treatment with afami-cel may offer improved quality of life to patients with metastatic synovial sarcoma compared with continuous chemotherapy.
Key Takeaways and Clinical Pearls on the Treatment of R/R MM in the Era of Bispecifics
The panel concludes its discussion with key takeaways on the evolving treatment landscape for multiple myeloma.
Treatment Practices in Metastatic Melanoma
Allison Betof Warner, MD, PhD, and the Oncology Brothers share clinical insights on treatment decisions for patients with metastatic melanoma.
Neoadjuvant Therapy in Melanoma
Medical oncologists provide comprehensive insights on neoadjuvant therapy options for patients with melanoma.
Treatment Algorithm for Stage IIB and Beyond Melanoma
Allison Betof Warner, MD, PhD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment practices for patients with stage IIB and beyond melanoma.